PDCD1 and melanoma: As a first step, we designed and optimized a multiplex immunohistochemistry (mIHC)-based assay to assess expression levels of Nodal in tissue specimens collected from a training set of 3 patients diagnosed with melanoma prior to treatment with anti-PD1 immune checkpoint inhibitors (Methods section; Figure 1).